Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients

INTRODUCTION: Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or...

Descripción completa

Detalles Bibliográficos
Autores principales: van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., Beijnen, J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754411/
https://www.ncbi.nlm.nih.gov/pubmed/29043410
http://dx.doi.org/10.1007/s00280-017-3455-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754411/
https://www.ncbi.nlm.nih.gov/pubmed/29043410
http://dx.doi.org/10.1007/s00280-017-3455-x

Ejemplares similares